Skip to main content

Recent News & Research

lungevity
FundingResearch

Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award

*November 2023* WASHINGTON, DC (November 1, 2023) – LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer. EGFR Resisters, a vibrant patient-led community advocating for improved treatment options for patients with EGFR-positive lung cancer,…
laurabbook@gmail.com
December 24, 2023
PR Newswire
ResearchTreatments

Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

*September 2023* RARITAN, N.J., Sept. 28, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), in combination with lazertinib, an oral third-generation EGFR tyrosine kinase…
laurabbook@gmail.com
December 24, 2023
OBR Oncology
ResearchTreatments

Are New NSCLC Findings Practice Changing, or Is PFS Boost Not Enough?

*October 2023* Findings from the FLAURA2 study, presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, showed that chemotherapy added to osimertinib in the first-line setting significantly increased progression-free survival (PFS) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, without data…
laurabbook@gmail.com
December 24, 2023
MEDPAGE TODAY
ResearchTreatments

Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC

*September 2023* SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in "clinically meaningful and durable efficacy" in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), according to the phase II HERTHENA-Lung01 trial. Among the…
laurabbook@gmail.com
December 24, 2023
Go2 logo
Coping With Cancer

Scanxiety: Tips from a Survivor and Expert

*September 2023* by Alison Mayer Sachs, MSW, LSW, OSW-C, FAOSW, Director, Community Outreach & Cancer Support, Services, Eisenhower Lucy Curci Cancer Center, Eisenhower Medical Center and lung cancer survivor “Scanxiety” is a term that people with cancer use to describe the anxiousness and fear they experience before, during, and after scans…
laurabbook@gmail.com
December 24, 2023
ResearchTreatments

Clinician Spotlight: Dr. Josh Reuss

*October 2023* This month we have the honor of featuring Dr. Josh Reuss, Assistant Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center Washington, DC. Dr. Reuss participated in the 2021 EGFR Resisters Research Summit and was a ‘Breakout Session’ winner for his research on A Phase II Open-label Study…
laurabbook@gmail.com
December 24, 2023